baber/WOPTO huggingface dataset:
Patent NZ-542664-A (NZ)
Title: Quinazolines useful as inhibitors of voltage-gated sodium channels and calcium channels
Inventor: GONZALES JESUS E
IPC: A61K31/5377
Filed: 2004-03-03
Abstract: The disclosure relates to quinazoline compounds of formula (IA-ii) useful as inhibitors of voltage-gated sodium channels and calcium channels, wherein the variables are as defined in the specification. Also described are pharmaceutically acceptable compositions comprising the compounds of formula (I) and their use for the manufacture of a medicament for treating or lessening the severity of a disease, disorder, or condition selected from acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or an epilepsy condition, a neurodegenerative disorder, a psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, a movement disorder, a neuroendocrine disorder, ataxia, multiple sclerosis, irritable bowel syndrome, or incontinence.
Patent NZ-542824-A (NZ)
Title: Sensor for detecting an analyte using silver nanoparticles
Inventor: BRENNAN MARGARET ELIZABETH
IPC: B22F1/054
Filed: 2004-03-29
Abstract: Disclosed is a sensor comprising discrete silver nanoparticles in which substantially all of the surfaces of the silver nanoparticles are available for interaction with an analyte or for functionalisation with a receptor which is capable of interacting with an analyte. Discrete silver nanoparticles that are colloidal in nature are preparated by forming the nanoparticles in the presence of a silver seeds and a polymeric stabiliser such as PVA.
Patent NZ-544934-A (NZ)
Title: Outcome-based asset management
Inventor: LORD TREVOR ROY
Filed: 2006-01-25
Abstract: A computer-implemented method of applying an outcome-based quality assurance process to the life management or reliability assurance of an asset is disclosed. The computer-implemented method includes the steps of: (a) determining a plurality of interventions available for managing the assets, (b) determining one or more individual quality of outcome values, wherein each individual quality of outcome value represents the quality of outcome of an intervention, (c) determining one or more cumulative quality of outcome values, wherein each cumulative quality of outcome value represents the quality of outcome of a combination of two or more interventions, (d) storing data relating to the individual and cumulative quality of outcome values in computer memory, and (e) selecting an intervention or a combination of two or more interventions based on the individual or cumulative quality of outcome values.
Patent NZ-544957-A (NZ)
Title: 2-Methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts
Inventor: FROSTRUP BRIAN
IPC: A61P25/00
Filed: 2004-07-29
Abstract: Disclosed are the (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts, such as L-tartrate monohydrates and anhydrates. The salts are useful as monoamine neurotransmitter re-uptake inhibitors and in a method for therapy as well as to prepare pharmaceutical compositions.
Patent NZ-545370-A (NZ)
Title: Louvre blade with covering applied thereto
Inventor: COPPO EDWARD ERNEST
IPC: E06B9/386
Filed: 2006-02-16
Abstract: A louvre blade has a core and a covering to cover at least a part of the core. The covering is bonded to the core of the louvre blade.
Patent NZ-546224-A (NZ)
Title: A method of communicating with a deployed product using a microserver card
Inventor: LODA DAVID C
Filed: 2004-10-04
Abstract: A method of communicating with a deployed product (14) is disclosed. The method comprises: (a) installing a microserver (12) into an electronic control box of a deployed product (14), wherein the microserver (12) acts as both a client and a server; (b) hosting a web page on the microserver (12), where the web page has an IP address available for a plurality of Internet protocols; and (c) accessing the web page wirelessly over the Internet.
Patent NZ-546284-A (NZ)
Title: Coumarin derivatives, process for their production and use thereof
Inventor: TERASHITA ZEN-ICHI
Filed: 2003-01-09
Abstract: Disclosed are coumarin derivatives of formula I' wherein R1 is a hydrogen atom, a halogen atom, or C1-7 alkyl group, R2 is a hydroxyl group or an optionally halogenated C1-4 alkoxy group and all other substituents are as defined in the specification. These compounds have lipid-rich plaque regressing activity and/or ACAT inhibitory activity which is useful for preventing or treating acute coronary syndrome such as acute myocardial infarction and unstable angina, peripheral artery occlusion, hyperlipemia, cerebral infarction, cerebral apoplexy, arteriosclerosis, Alzheimer's disease, or the like, or preventing or treating restenosis after PTCA or after stent placement.
Patent NZ-547231-A (NZ)
Title: Novel hydroxamic acid esters and pharmaceutical use thereof
Inventor: FENSHOLDT JEF
IPC: C07D401/12
Filed: 2004-12-02
Abstract: Disclosed are compounds of formula (I), wherein the substituents are as defined in the specification. The compounds are useful for treating diseases associated with deregulated angiogenesis, such as cancer.
Patent NZ-553029-A (NZ)
Title: Isoindoline compounds and methods of their use
Inventor: MULLER GEORGE W
IPC: A61K31/4035
Filed: 2005-07-27
Abstract: Disclosed is a compound selected from the seven isoindoline derivatives of the pictured formula, of a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof. Also disclosed is the use of the compound for treating cancer, for treating a disease associated with undesired angiogenesis, or for reducing or inhibiting PDE4 activity.
Patent NZ-553946-A (NZ)
Title: Method and device for franking mail
Inventor: MEYER BERND
Filed: 2005-09-20
Abstract: A method for franking mail in which a postage indicium is requested by an operating and printing unit (20) among a number of operating and printing units is provided. The postage indicium being generated in a franking unit (10), made accessible to the operating and printing unit (20) and applied onto the mailpieces in the operating and printing unit (20). A transaction request is transmitted from the operating and printing unit (20) to an autonomous logging unit (40), where: at least excerpts of the transaction request are recorded in the autonomous logging unit (40); the transaction request is forwarded from the autonomous logging unit (40) to the franking unit (10); the transaction request is processed by the franking unit; a result of the processing of the transaction request is transmitted from the franking unit (10) to the autonomous logging unit (40); at least excerpts of the result of the processing of the transaction request are recorded and stored (B6) in the autonomous logging unit (40); the result of the processing of the transaction request is forwarded from the autonomous logging unit (40) to the operating and printing unit (20); and making use of the result of the transaction request, a postage indicium is applied onto the mailpiece.
Patent NZ-554236-A (NZ)
Title: Host-vector system for antibiotic-free cole1 plasmid propagation
Inventor: GRABHERR REINGARD
IPC: C12N15/70
Filed: 2005-09-08
Abstract: Provided is a non-naturally occurring bacterial cell containing i) a DNA sequence encoding a protein the expression of which is to be regulated, and, operably associated thereto, ii) a DNA sequence encoding an RNA sequence that mimics an RNA II sequence, or parts thereof, and that is complementary to an RNA I sequence that is transcribable from a plasmid with a ColE1 origin of replication. Further provided is the host-vector system and the plasmid to be used in the host-vector system.
Patent NZ-566012-A (NZ)
Title: Quinoline derivatives as antibacterial agents
Inventor: ANDRIES KOENRAAD JOZEF LODEWIJK MARCEL
IPC: A61K31/4709
Filed: 2006-07-31
Abstract: Disclosed is the use of quinoline derivatives of formula (Ia) or (Ib) for the manufacture of a medicament for the treatment of a bacterial infection, wherein the substituents are defined within the specification, and provided that the bacterial infection is other than a Mycobacterial infection. Other quinoline derivatives which comprise a naphthalene group are also disclosed. The use of these derivatives in combination with other antibacterial agents, for the manufacture of a medicament for the treatment of a bacterial infection other than a Mycobacterial infection is also disclosed.
Patent NZ-579102-A (NZ)
Title: A portable electronic payment, information, or ID card with a deformation sensing means
Inventor: NIELSEN FINN
IPC: G07F7/08
Filed: 2008-02-27
Abstract: A portable card is and a method of operating a portable card disclosed. The portable card comprises an electronic circuit adapted to operate in a first and a second mode, a sensor electronically connected to the circuit, and a power source connected to the circuit. The circuit comprises a processor to transition from the first mode to the second mode when receiving a signal from the sensor where the first mode is a sleep mode and the second mode is an operating mode of the processor. The sensor is a piezo electric element, which is not connected to the power source, and which outputs the signal directly to the processor when being deformed.
Patent NZ-579158-A (NZ)
Title: Engineered anti-il-23p19 antibodies
Inventor: PRESTA LEONARD G
IPC: A61K39/395
Filed: 2008-02-21
Abstract: Disclosed is an interleukin-23 p19 (IL-23p19) antibody or antigen binding fragment comprising: a) a light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein: CDRL1 comprises the sequence of SEQ ID NO: 36; CDRL2 comprises the sequence of SEQ ID NO: 41; and CDRL3 comprises the sequence of SEQ ID NO: 46; and b) a heavy chain variable domain, or antigen binding fragment thereof, comprising CDRH1, CDRH2 and CDRH3, wherein: CDRH1 comprises the sequence of SEQ ID NO: 19; CDRH2 comprises the sequence of SEQ ID NO: 25; and CDRH3 comprises the sequence of SEQ ID NO: 31. Further disclosed is an isolated nucleic acid encoding said antibody or antigen binding fragment, and an expression vector and host cell comprising said nucleic acid. Also disclosed is a method for producing said antibody or antigen binding fragment, and a pharmaceutical composition comprising said antibody or antigen binding fragment. Also disclosed is the use of the antibody or antigen binding fragment in the manufacture of a medicament for the treatment of arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, diabetes, and cancer.
Patent NZ-579284-A (NZ)
Title: Improved disinfestation method
Inventor: RYAN ROBERT FRANCIS
IPC: A01M13/00
Filed: 2008-02-25
Abstract: Disclosed is a method of disinfecting plant material in a chamber, the method comprising a) aerosolising a pesticide to form droplets or particles from about 0.5 to about 30 microns in diameter, b) mixing the aerosol with a volume of a diluent gas to create a first pesticide mixture, c) introducing the first pesticide mixture into the chamber, and d) circulating the first pesticide mixture throughout the majority of the chamber to form a substantially homogenous second pesticide mixture. Also disclosed is an apparatus for disinfesting plant material in a chamber comprising a) a pesticide supply for supplying a vaporising or aerosolised pesticide, b) a mixing device for receiving and mixing the pesticide vapour or aerosol with a volume of diluent gas, and producing a first pesticide mixture; c) a transfer system for introducing the first pesticide mixture into the chamber; and d) a circulating system for circulating the first pesticide mixture throughout the majority of the chamber to form a substantially homogenous second pesticide mixture.
Patent NZ-585392-A (NZ)
Title: Metering voltage and wirelessly transmitting an indicator when voltage is outside of a range for greater than a set duration
Inventor: RICHESON KEITH D
IPC: G01D4/00
Filed: 2008-12-22
Abstract: 585392 Disclosed is a system (110) for monitoring voltage in a wireless network of meters. The system (110) is comprised of a plurality of meters (114a, 114b) each receiving respective input voltages. Each meter (114a, 114b) samples an input voltage, periodically determines voltage values from the sampled input voltage and generates an indication of a voltage irregularity when at least one of the voltage values is determined to be beyond a voltage threshold for a predetermined duration. The meter (114a, 114b) does not generate the indication of the voltage irregularity when the at least one of the voltage values is determined to be beyond the voltage threshold for less than the predetermined duration. The system (110) also includes a collector (116) communicating wirelessly with each of the plurality of meters (114a, 114b) to form a fixed wireless metering network. The collector (116) receives generated indications from each of the plurality of meters (114a, 114b) and identifies a select group of meters among the plurality of meters (114a, 114b) that have reported an indication.
Patent NZ-586416-A (NZ)
Title: Methods of treating hematologic cancers using pnp inhibitors such as forodesine in combination with alkylating agents or anti-cd20 agents
Inventor: BANTIA SHANTA
IPC: A61K45/06
Filed: 2008-12-10
Abstract: Disclosed is the use of (a) Forodesine (7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl]-1,5-dihydropyrrolo[2,3-e]pyrimidin-4-one or Immucillin H), (b) Bendamustine (4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid) and optionally (c) an anti-CD20 agent, in the manufacture of a medicament for treating a hematologic cancer in a subject in need thereof, wherein the medicament is formulated for separate, sequential or simultaneous administration of (a), (b) and (c). An example of an anti - CD20 agent is Rituximab which is an antibody. Examples of hematologic cancers are non-Hodgkin's lymphoma, chronic lymphocytic leukaemia and acute lymphoblastic leukaemia. Also disclosed is a pharmaceutical composition comprising Forodesine, Bendamustine and an optional anti-CD20 agent.
Patent NZ-587142-A (NZ)
Title: Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
Inventor: HEINELT UWE
IPC: A61P7/02
Filed: 2009-01-23
Abstract: Disclosed are triazolo compounds of formula I, stereoisomers, tautomers and salts thereof, and methods for their preparation. Specific examples of compounds of formula I include: 1-{ 2-[3-acetylamino-5-(pentafluorosulfanyl)phenyl]-2-oxoethyl} -3-amino-6-ethoxy-[1,2,4]triazolo[4,3-b]pyridazin-1-ium trifluoroacetate, 3-amino-1-[2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-oxoethyl]-6-trifluoromethyl-[1,2,4]triazolo[4,3-a]pyridin-1-ium, 3-amino-1-[2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-oxoethyl][1,2,4]triazolo[4,3-a]pyridin-1-ium, 3-amino-1-[2-(3-tert-butyl-4-methoxy-5-morpholin-4-ylphenyl)-2-oxoethyl]-6-trifluoromethyl-[1,2,4]triazolo[4,3-a]pyridin-1-ium, and 3-amino-1-[2-(3-tert-butyl-4-methoxy-5-morpholin-4-ylphenyl)-2-oxoethyl]-5-methyl-7-trifluoromethyl-[1,2,4]triazolo[4,3-a]pyridin-1-ium. Also disclosed is the use of compounds of formula I for treating disorders associated with thromboses, embolisms, hypercoagulability, fibrotic changes or inflammatory disorders, such as myocardial infarction, angina pectoris and other types of acute coronary syndrome, stroke, peripheral vascular disorders, deep vein thrombosis, pulmonary embolism, embolic or thrombotic events caused by cardiac arrhythmias, cardiovascular events such as restenosis following revascularization and angioplasty and similar procedures such as stent implantations and bypass operations or reduction of the risk of thrombosis following surgical procedures such as knee and hip joint operations or procedures leading to contact of blood with foreign surfaces, such as for dialysis patients and patients with indwelling catheters or disseminated intravascular coagulation, sepsis and other intravascular events associated with inflammation, atherosclerosis, diabetes and the metabolic syndrome and the sequelae thereof, tumor (tumour) growth and tumor metastasis, inflammatory and degenerative articular disorders such as rheumatoid arthritis and arthrosis, impairments of the hemostatic system such as fibrin deposits, fibrotic changes in the lung such as chronic obstructive pulmonary disease, adult respiratory distress syndrome or fibrin deposits in the eye following eye operations or prevention and/or treatment of scarring.
Patent NZ-587368-A (NZ)
Title: Method of identifying GLP- 1 secretagogues
Inventor: CHU ZHI-LIANG
IPC: A61K31/00
Filed: 2006-01-09
Abstract: Provided is a process of preparing a pharmaceutical composition comprising a GPRl19 agonist having the effect of a GLP-l secretagogue, the process comprising: (a) contacting the GPR1l9 agonist in vitro with a mammalian enteroendocrine cell; and (b) determining whether the GPR1l9 agonist stimulates GLP-I secretion from the mammalian enteroendocrine cell, wherein the ability of the GPRl19 agonist to stimulate GLP-l secretion from the mammalian enteroendocrine cell is indicative of the agonist being the GLP-I secretagogue; and (c) formulating the GPR1l9 agonist with a pharmaceutically acceptable carrier as a pharmaceutical composition. (62) Divided Out of 556219
Patent NZ-591767-A (NZ)
Title: Device for measuring gas output from a sample in a container, where the container is in a tank and the meter is in the tank lid
Inventor: MADDREN JESS
IPC: B01L5/02
Filed: 2009-09-18
Abstract: 591767 A device for measuring fluid produced by a substance, the device including a container 5 for holding the substance, and a measuring apparatus 20, the measuring apparatus 20 being in fluid communication with the container 5 such that release of fluid from the substance displaces measuring fluid in the measuring apparatus 20, thereby allowing for the fluid produced by the substance to be measured. The container 5 is held in a tank body 1. The tank body 1 has a lid 12 attached. The lid 12 is configured to hold the measuring apparatus 20.
Patent NZ-595689-A (NZ)
Title: Compositions for immunising against staphylococcus aureus
Inventor: FIASCHI LUIGI
IPC: A61K39/085
Filed: 2010-04-14
Abstract: 595689 Discloses an antigenic composition comprising sta006, sta011 and further comprising at least one other staphylococcal antigen which is typically esxA, esxB and/or hla (however can be selected from a list of 164 other antigens). Further discloses the use of the composition in the treatment of a Staphylococcus aureus infections.
Patent NZ-597254-A (NZ)
Title: Nasal mask system
Inventor: OZOLINS ANGELENE MARIE
IPC: A61M16/06
Filed: 2010-05-28
Abstract: 597254 A nasal mask including a sidewall and a cushion. The cushion includes a relatively thick backup band (6544) formed from a resilient flexible material and extending from the sidewall to form respective cantilevers in a top lip region, a comer region and a side of nose region of the cushion, the cantilevers each having a length and a thickness and the cantilevers defining respective lip region, comer region and side of nose region stiffness's. The comer region cantilever is stiffer than the top lip region cantilever in a direction normal to the plane of the face. The cushion further includes a relatively thin facial flap (6546). The facial flap is inwardly curving and extends around the perimeter of the cushion to define the rearward sealing surface of the cushion. An inner edge of the facial flap defines an orifice through which a portion of a nose of the patient passes in use.
Patent NZ-602882-A (NZ)
Title: Papaver somniferum with high concentration of codeine
Inventor: FIST ANTHONY J
IPC: A01H6/64
Filed: 2009-05-28
Abstract: Patent No. 602882 Disclosed is a plant of Papaver somniferum having a high codeine trait, wherein codeine is the predominant alkaloid, and having substantially no oripavine or morphine, said plant being obtained by crossing a first P. somniferum parent plant containing thebaine and having substantially no oripavine, morphine or codeine with a second P. somniferum parent plant containing morphine, and producing an F2 generation of plants from the said cross and selecting plants containing high contents of codeine, and substantially no oripavine or morphine, wherein said first P.somniferum parent plant is a plant grown from seed of ATCC PTA 9109.
Patent NZ-603913-A (NZ)
Title: Method of engrafting cells from solid tissues
Inventor: TURNER RACHAEL
IPC: A61K35/407
Filed: 2011-05-06
Abstract: Discloses use of a mixture for the manufacture of a medicament for engrafting liver cells into a liver in a diseased or dysfunctional condition in a subject, the mixture comprising: a. normal liver or biliary tree cells wherein the cells are not human totipotent cells; b. combined with endothelial cell precursors, stellate cell precursors and one or more biomaterials to form a mixture; c. optionally, the mixture is combined with nutrient medium, signalling molecules, extracellular matrix components, or a combination thereof; wherein upon introducing the mixture of step (b) or (c) into the liver of the subject, a substantial portion of the cells introduced take up residence in or on at least a portion of the liver in vivo. Also discloses similar methods for repairing tissue and localising cells to a surface.
Patent NZ-606008-A (NZ)
Title: Method for injecting a feed gas stream into a vertically extended column of liquid
Inventor: HICKEY ROBERT
IPC: C12R1/01
Filed: 2011-06-30
Abstract: The disclosure relates to a process for converting a feed gas stream, comprising at least one of CO or a mixture of CO2 and H2, to a liquid product by contact with a fermentation liquid, wherein the liquid product reduces the surface tension of the fermentation liquid, wherein the process uses the gas stream at a relatively low pressure to eliminate the use of a compressor. The process uses a liquid stream as the primary energy input to a gas injector that intensely mixes gas and the liquid with reduced compression costs while the presence of the liquid product maintains the gas-liquid dispersion as it flows downward to build a static pressure head. The process lowers the required gas pressure by adjusting the elevation of the gas injector such that a conduit receives the gas-liquid dispersion from the outlet of the injector and confines it as it travels downward to enter the bottom of a column of liquid. The liquid product provides a surface acting agent that prolongs the creation and duration of microbubbles in the gas-liquid dispersion.